Navigation Links
New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA)
Date:11/9/2010

ATLANTA, Nov. 9, 2010 /PRNewswire/ -- The addition of Cimzia® (certolizumab pegol; CZP) to current therapy was associated with a rapid clinical response, improved function and reduced disease activity in a diverse group of adult rheumatoid arthritis (RA) patients reflecting those seen in daily clinical practice (including those with prior TNF-inhibitor use).  These positive clinical trial data were presented during the American College of Rheumatology's (ACR) 2010 Annual Scientific Meeting in Atlanta, November 7-11. Cimzia®  is approved for the treatment of adults with moderately to severely active rheumatoid arthritis.

"There are patients who live with little relief from the painful symptoms of rheumatoid arthritis due to failed therapies or the severity of the condition," said Roy Fleischmann, MD, clinical professor in the Department of Internal Medicine at the University of Texas Southwestern Medical School.  "These data emphasize that treatment with Cimzia® can substantially provide rapid improvements and help reduce disease activity regardless of the patient's disease history in many of these patients."

The data presented were from the REALISTIC (RA Evaluation in Subjects Receiving TNF Inhibitor Certolizumab Pegol) multicenter phase IIIb study, which included a 12-week, randomized, double-blind (DB), placebo-controlled phase followed by an open-label extension (OLE) (greater than or equal to 16 weeks).  REALISTIC was designed to investigate the safety and efficacy of CZP in a broad patient population with active RA more closely resembling routine clinical practice, versus the pivotal trials, including patients with/without prior TNF-inhibitor exposure, with/without concomitant methotrexate or other disease-modifying anti-rheumatic drugs (DMARDs); and varying lengths of disease duration.

The primary endpoint of an ACR20 score at week 12 was met.  At week 12, more than half (51.1%) of patients in the
'/>"/>

SOURCE UCB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Rapid and Long-term Clinical Responses Observed in Rheumatoid Arthritis Patients Taking Cimzia® (certolizumab pegol), According to Data Being Highlighted During ACR Meeting
2. UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohns Disease
3. Long-Term Data on Cimzia® (certolizumab pegol) for Moderate to Severe Crohns Disease to be Highlighted at ACG Meeting
4. New Data Show CIMZIA(R) (certolizumab pegol) Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohns Patients
5. CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years
6. CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohns Disease Patients
7. CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohns Patients
8. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
9. Marken Rapidly Responds to Global Supply Chain Security Measures
10. Biosimilar Erosion of Branded ESA Market Share Will be More Rapid in the U.S. Than in Europe
11. Results of Boehringer Ingelheim Oral Hepatitis C Protease Inhibitor and Polymerase Inhibitor Combination Phase Ib Trial Shows Rapid Viral Response Without Use of Pegylated Interferon
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Quebec , Jan. 15, 2014  Valeant Pharmaceuticals International, ... announced that the applicable waiting period under the Hart-Scott-Rodino ... the previously announced tender offer by its indirect wholly-owned ... outstanding shares of common stock of Solta Medical, Inc. ...
(Date:1/14/2014)... HeartWare International, Inc . (NASDAQ: ... circulatory support technologies that are revolutionizing the treatment of ... for the fourth quarter of 2013 will be approximately ... $208 million. "Our full-year revenue growth of ...
(Date:1/14/2014)... , Jan. 14, 2014 /PRNewswire-iReach/ -- Acumed,s new SLIC ... guide with accompanying instrumentation to place and insert the ... the soft tissue (e.g. ligament) repair or reconstruction as ... heals. (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ) ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3
... 2011 Spherix Incorporated (NASDAQ: SPEX ) ... metabolic syndrome and atherosclerosis, and providers of technical and ... companies -- today announced that Dr. Claire Kruger, Chief ... presenting a corporate overview at the Rodman & Renshaw ...
... Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals ... Executive Officer, will present at the Rodman and Renshaw ... 2:25pm ET at the Waldorf Astoria Hotel in New ... Founded in 2008, Omthera Pharmaceuticals, Inc. ...
Cached Medicine Technology:Spherix Incorporated to Present at the Rodman & Renshaw 13th Annual Healthcare Conference 2
(Date:4/18/2014)... Research Institute at Virginia Mason (BRI) recently received a ... metastatic breast cancer reduces both the growth of primary ... have found in models of the disease that blocking ... percent and can keep the tumor from metastasizing or ... comes from the National Cancer Institute of the National ...
(Date:4/18/2014)... could lead to potential new treatments for breaking the ... , Fibrosis, or scarring, is a hallmark of the ... can lead to serious organ damage and, in some ... centers on findings made by Swati Bhattacharyya, PhD, research ... a specific protein plays in promoting fibrosis. , ...
(Date:4/17/2014)... that could be used to provide relief from ... made the discovery when researching how pain occurs ... , Dr Marzia Malcangio said: "We have been ... our findings could help chemotherapy patients who suffer ... effect of some chemotherapy drugs (such as vincristine) ...
(Date:4/17/2014)... School of Medicine report that older women, plucky individuals ... are more likely to be compassionate toward strangers than ... this month,s issue of the International Journal of ... with better health and well-being as we age, the ... outcomes of individuals whose deficits in compassion put them ...
(Date:4/17/2014)... Northwestern University synthetic biology team has created a ... programmable therapeutics that could travel the body and ... , Engineering cell-based, biological devices that monitor and ... clinical synthetic biology. However, no existing technology enabled ... patient,s physiological state and respond in a customized ...
Breaking Medicine News(10 mins):Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:New clues on tissue scarring in scleroderma 2Health News:New pain relief targets discovered 2Health News:The ilk of human kindness 2Health News:Building 'smart' cell-based therapies 2
... SILVER SPRING, Md., Dec. 24 The American Nurses Association (ANA), ... for passing H.R. 3590, " The Patient Protection and Affordable ... vote of 60-39. ANA had urged passage of the legislation and ... members of Congress, was read on the Senate floor by Majority ...
... , , WASHINGTON, Dec. 24 ... Senate voted to pass the Patient Protection and Affordable Care ... bill on Christmas Eve, after overcoming a series of procedural ... stop the bill from ever reaching the Senate floor for ...
... Dec. 24 The American ... of legislation that holds the promise of more comprehensive coverage ... those without. , We are pleased that the ... our association,s principles for comprehensive health reform, and that the ...
... 24 The following statement is attributable to J. James ... Senate took an historic vote to improve our nation,s health ... strengthening the private insurance market to better serve the patients ... the bill because it contains a number of key improvements ...
... well-tolerated, researchers say , WEDNESDAY, Dec. 23 (HealthDay News) -- ... an effective treatment for Ewing,s sarcoma, a cancer that affects ... boys. , The drug must undergo two more phases of ... 23 online edition of The Lancet Oncology . , ...
... before proposal can become law , THURSDAY, Dec. 24 (HealthDay ... Eve gift on Thursday with passage of a landmark health ... Americans. , Obama said the Senate bill contains 95 percent ... inauguration on Jan. 20. "Every single criteria for reform that ...
Cached Medicine News:Health News:Senate Passes Landmark Health Care Reform Bill 2Health News:DNC Chairman Tim Kaine Calls Senate Vote Historic, Says Landmark Health Reform Bill Is a Victory for the American People 2Health News:APA Statement on Senate Passage of Health Care Reform Legislation 2Health News:AMA: Senate Bill Passage Historic, More Work to Do in Conference 2Health News:Senate Passes Health Reform Package 2Health News:Senate Passes Health Reform Package 3Health News:Senate Passes Health Reform Package 4
... SuperAnchors are titanium alloy implants ... to bone. They are indicated ... required. The SuperAnchor uses four ... while maintaining small size. The ...
The Mini-Revo suture anchor is designed primarily for arthroscopic and open Bankart shoulder repair. Additional applications include other shoulder repair procedures, as well as use in small joints....
... protection' -- providing complete protection from initial ... with side branches. , ,Proxis is ... not require the attachment or exchange of ... ,Proxis is compatible with all standard ...
... electrophysiology system on the market today, the ... patented "C inside a C" design offering ... ultimate in patient access and flexibility. Usable ... minimizes equipment footprint and can be parked ...
Medicine Products: